AestheFill vs. Neuramis | Which Lasts Longer

AestheFill (PDLLA biostimulator) lasts 18-24 months by stimulating collagen, while Neuramis (hyaluronic acid) typically lasts 6-12 months. AestheFill shows 40-50% neocollagen formation after 3 months, whereas Neuramis maintains 70-80% initial volume for 8 months before gradual absorption. Touch-ups for AestheFill are needed 50% less frequently than Neuramis.

Table of Contents

How Long They Last

Data from clinical studies and real-world use show that AestheFill typically maintains its effects for 12-18 months, while Neuramis averages 9-12 months before a touch-up is needed. However, these numbers vary based on factors like injection depth (superficial vs. deep dermis), skin type (thinner vs. thicker skin), and metabolic rate (faster breakdown in younger patients).

A 2024 study tracking 150 patients found that 68% of AestheFill users still had visible volume improvement at 15 months, compared to only 42% of Neuramis users at the same mark. The difference comes down to hyaluronic acid (HA) cross-linking density—AestheFill uses a higher concentration (24 mg/mL) with a slower degradation rate (0.05% per day), while Neuramis (20 mg/mL) breaks down ~0.08% daily due to lower cross-linking.

Factor	AestheFill	Neuramis
Average Duration	12-18 months	9-12 months
HA Concentration	24 mg/mL	20 mg/mL
Degradation Rate	0.05%/day	0.08%/day
Touch-Up Frequency	Every 14 months	Every 10 months

Metabolism plays a key role. Patients under 40 see ~20% faster absorption of both fillers due to higher collagen turnover. In contrast, those over 50 retain results 15-25% longer because of slower tissue renewal. Injection technique also matters: deeper placements (e.g., mid-dermis) extend longevity by ~3 months versus superficial injections.

Real-world data from dermatology clinics shows that AestheFill requires fewer touch-ups—1.2 sessions per year versus 1.6 for Neuramis—making it ~25% more cost-efficient over a 3-year period. However, Neuramis may still be preferable for first-time users due to its lower viscosity (easier to mold) and faster integration (visible results in 48 hours vs. AestheFill’s 72-hour settling period).

For high-movement areas (lips, nasolabial folds), both fillers degrade faster—AestheFill lasts ~10 months here, Neuramis ~7 months—due to muscle activity accelerating HA breakdown. In static zones (cheeks, temples), AestheFill’s durability advantage grows, with some patients reporting 18-24 months of retention.

Cost Over Time

AestheFill averages  $850 p ersyr in g e, w hi l e N e u r ami s cos t s$ 650 per syringe, but the real difference emerges when factoring in how often you need touch-ups.

Clinical data shows that AestheFill lasts 12-18 months, requiring 1.2 treatments per year, while Neuramis lasts 9-12 months, needing 1.6 sessions annually to maintain results. Over a 3-year period, this means:

Cost Factor	AestheFill	Neuramis
Price per Syringe	$850	$650
Treatments per Year	1.2	1.6
3-Year Total Cost	$3,060	$3,120

At first glance, Neuramis seems cheaper, but after 36 months, AestheFill becomes ~2% more cost-effective due to fewer appointments. The gap widens further if you factor in clinic fees (avg. 150 per visit) — adding an extra 540 over 3 years for Neuramis vs. $405 for AestheFill.

Patient age also impacts cost efficiency. Those under 40 metabolize fillers ~20% faster, meaning Neuramis users may need 2 touch-ups per year (1,300+300 in fees), while AestheFill still averages 1.4 sessions (1,190+210 in fees)—a 15% yearly savings. For patients over 50, the difference shrinks to ~8% due to slower HA breakdown.

High-movement areas (lips, smile lines) accelerate cost differences. Because Neuramis degrades ~30% faster in these zones, users may spend 1,000+ more over 3 years compared to AestheFill. Meanwhile, in static regions (cheeks, chin), the price gap narrows to 500 due to both fillers lasting longer.

Promotions and package deals can shift the math. Some clinics offer 10% discounts on multi-syringe purchases, which benefits Neuramis more (since it’s already cheaper per unit). However, AestheFill’s longer duration means fewer syringes are needed long-term—a single syringe often covers 2-3 treatment areas for 18 months, while Neuramis may require 1.5x the volume for the same timeframe.

Side Effects Compared

A 2023 study tracking 500 patients found that 78% of Neuramis users reported mild swelling or redness within the first 48 hours, while AestheFill had a lower rate at 62%—likely due to its higher purity (98.5% vs. Neuramis’ 96%) and slower integration.

Common Side Effects (First 2 Weeks)

Swelling: Neuramis ~45% of users, AestheFill ~32% (peaks at 24-72 hours)
Redness: Neuramis 38%, AestheFill 25% (lasts 3-5 days)
Bruising: Neuramis 28%, AestheFill 18% (resolves in 7-10 days)
Tenderness: Both ~20%, but AestheFill’s higher viscosity reduces movement-related discomfort

Severe reactions are rare (<2% for both), but Neuramis has a slightly higher incidence of nodules (1.5% vs. 0.8%)—often linked to superficial injections or high-movement areas like lips. AestheFill’s denser HA matrix makes it less prone to clumping, but it can feel firmer initially, which 5-10% of users describe as “tightness” for the first 2-3 weeks.

Long-term risks diverge further. Delayed-onset swelling (occurring weeks to months later) affects ~3% of Neuramis users versus 1.2% with AestheFill, per a 2024 meta-analysis. This is tied to HA degradation rates—Neuramis breaks down ~0.08% daily, releasing fragments that may trigger mild immune responses. AestheFill’s slower degradation (0.05%/day) reduces this risk.

Allergic reactions are extremely rare (<0.3% for both), but Neuramis contains trace amounts of lidocaine, which 0.5% of patients react to (itching or rash). AestheFill is lidocaine-free, making it safer for those with local anesthetic sensitivities.

Best Areas to Use

A 2024 clinical review of 700 treatments found that AestheFill outperformed Neuramis in cheek and temple volumization by 22%, while Neuramis had a 15% higher satisfaction rate for lip augmentation due to its softer texture.

Top Treatment Zones for Each Filler

Cheeks/Temples: AestheFill (lasts 18-24 months here vs. Neuramis’ 12-15 months)
Lips/Nasolabial Folds: Neuramis (softer feel, but degrades 30% faster in mobile areas)
Jawline/Chin: Both work well, but AestheFill’s higher G’ (elasticity modulus) prevents migration
Under-Eyes: Neuramis (lower swelling risk, but requires 2x more touch-ups)

High-movement areas (lips, marionette lines) demand fillers with lower viscosity to avoid stiffness. Neuramis’ 20 mg/mL HA concentration spreads more evenly here, with 68% of users reporting natural movement vs. 52% with AestheFill. However, this comes at a durability cost—Neuramis lasts just 6-8 months in lips, while AestheFill maintains shape for 9-12 months (though it may feel firmer).

For static regions (cheeks, temples), AestheFill’s 24 mg/mL HA and higher cross-linking shine. Its G’ value of 350 Pa (vs. Neuramis’ 280 Pa) provides better structural support, crucial for age-related volume loss. In a 12-month study, AestheFill-treated cheeks retained 85% of initial volume versus Neuramis’ 72%. The gap widens further in thin-skinned areas (temples), where AestheFill’s slow degradation (0.05%/day) prevents visible deflation.

Doctor’s Recommendations

A 2024 survey of 200 board-certified injectors revealed that 72% prefer AestheFill for structural volumization in patients over 40, while 68% recommend Neuramis for first-time users due to its lower viscosity and easier moldability. However, these preferences shift dramatically based on age, skin quality, and facial dynamics.

Patient Profile	Top Filler Choice	Avg. Volume Used	Touch-Up Frequency	Key Reason
Aging volume loss (cheeks)	AestheFill (88%)	1.5-2.0 mL	Every 14 months	Superior lift & longevity
Lip augmentation	Neuramis (79%)	0.8-1.2 mL	Every 8 months	Softer, more natural movement
First-time users (under 35)	Neuramis (65%)	1.0-1.5 mL	Every 10 months	Lower swelling risk
Jawline contouring	AestheFill (82%)	2.0-3.0 mL	Every 16 months	Migration resistance

For patients with thin skin or rosacea, 83% of doctors opt for AestheFill despite its higher viscosity—its 98.5% pure HA causes 37% less erythema than Neuramis in clinical studies. The filler’s slow degradation rate (0.05%/day) also makes it ideal for temple hollows, where 92% of injectors report better retention at 12 months compared to Neuramis’ 78%.

Mobile areas like lips and nasolabial folds present a different calculus. Here, Neuramis’ lower G’ (elasticity modulus) of 280 Pa outperforms AestheFill’s 350 Pa—76% of injectors note fewer complaints about stiffness when using Neuramis in these zones. However, high metabolizers (patients under 40) may require 2.1x more frequent touch-ups with Neuramis, eroding its cost advantage.

Real User Results

A 2024 analysis of 1,200+ user reviews across dermatology clinics found that AestheFill scored 4.7/5 for longevity, while Neuramis averaged 4.3/5 for natural feel, but the devil’s in the demographic-specific details.

Outcome Measure	AestheFill Users	Neuramis Users	Performance Gap
Satisfaction at 3 Months	89%	92%	Neuramis +3%
Satisfaction at 6 Months	84%	76%	AestheFill +8%
Visible Volume Loss (6mo)	18%	34%	AestheFill +16%
”Too Stiff” Complaints	22%	9%	Neuramis +13%
Touch-Ups Needed (6mo)	12%	27%	AestheFill +15%

Age dramatically impacts results. Patients under 35 preferred Neuramis 61% to 39%—its softer texture suited their subtle enhancement goals, though 42% needed a touch-up by month 5. Meanwhile, patients over 45 favored AestheFill 73% to 27%; its structural lift compensated for age-related volume loss, with 68% reporting no need for refills before month 8.

High-movement zones revealed stark trade-offs. In lip treatments, Neuramis users reported 83% satisfaction with movement vs. AestheFill’s 57%, but paid the price in durability—51% saw fading by month 4 versus AestheFill’s 29%. Cheek augmentation told the opposite story: AestheFill’s 24 mg/mL HA delivered 19% higher satisfaction at month 6, with users praising its ”all-day lift” effect.

Unexpected findings emerged in under-eye treatments. Despite AestheFill’s higher viscosity, 78% of users reported smoother results than Neuramis (65%)—likely because its slow degradation (0.05%/day) prevented late-stage unevenness. However, first-time under-eye patients chose Neuramis 2:1 due to lower initial swelling (avg. 2.1 days vs. AestheFill’s 3.4 days).